SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (1439)12/17/1998 7:20:00 PM
From: Michael Greene  Read Replies (3) of 2135
 
There is an article dated December 7, 1998 in "The scientist" which contains some comment from Dr. Folkman which should be of interest to Entremed investors.

the-scientist.library.upenn.edu

Folkman also thinks that finding the receptors that bind angiostatin and endostatin will improve antiangiogenesis techniques. "As soon as they are known, it means that chemists have a chance to try to find a substitute for the protein--a small molecule that could land on the receptor and do what the whole protein does." He also predicts that other groups will find more angiogenesis inhibitors that may be more stable and effective than angiostatin and endostatin: "There are going to be many angiogenesis inhibitors. They just keep coming."

Does anyone have any thoughts on the possibility that another company might cut out Entremed on AS and ES by finding a substitute for the protein--a small molecule that could land on the receptor and do what the whole protein does?

Michael
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News